Section 7.1 Laboratory

Laboratory Report #23

Date

Collection Date: July 26, 2022
Report Date: August 2, 2022

Laboratory

Quest Diagnostics

Performing Laboratory:
Quest Diagnostics / Nichols Institute
San Juan Capistrano, California

Ordering Physician

Dr. Maryam Saifi

Report Type

Specialized Allergy / Mast Cell Evaluation

Laboratory testing included:

Serum Tryptase

Original Report

PDF: Quest Diagnostics – July 26, 2022

One-Page Summary

Purpose of Testing

This specialized laboratory evaluation was performed as part of rheumatology/allergy-related investigation to evaluate for possible mast cell activation or mast cell disorders. Serum tryptase testing measures levels of tryptase, an enzyme released primarily from mast cells, and is commonly used in the evaluation of conditions such as mastocytosis and episodes involving mast cell degranulation.

Major Finding

Serum Tryptase

Result

6.5 mcg/L

Reference Range:

<11.0 mcg/L

Interpretation

The serum tryptase level was within the normal reference range.

This finding indicates:

No laboratory evidence of an elevated baseline mast cell burden.
No evidence from this test alone suggesting systemic mastocytosis.
No evidence of significant ongoing mast cell activation at the time of testing.

The report notes that the assay measures both alpha and beta tryptase forms, increasing sensitivity for detecting mast cell disorders and mast cell degranulation associated with anaphylaxis.

Clinical Significance

This test was not evaluating inflammation directly like ESR or CRP. Instead, it addressed a specific diagnostic question:

“Could mast cell activation or a mast cell disorder explain symptoms or inflammatory findings?”

The normal result helped exclude a mast cell disorder as a likely explanation for the previous systemic inflammatory episode.

Overall Interpretation

This specialized Quest Diagnostics evaluation showed a normal serum tryptase level of 6.5 mcg/L. The result provided reassuring evidence against systemic mastocytosis or significant mast cell activation as a contributor to the patient’s clinical history at the time of testing. This report is another example of the extensive diagnostic evaluation performed after the unexplained inflammatory illness of 2021.

Longitudinal Significance

This report contributes to:

Autoimmune Evaluation
Systemic Inflammatory Illness Timeline
Allergy / Immunology Evaluation
Differential Diagnosis Archive
Rheumatology Consultation Summary

Clinical Importance

⭐⭐⭐ Diagnostic Exclusion Study

Although this report contains only one laboratory value, it is clinically important because it helped eliminate another possible explanation for the prior inflammatory symptoms.

Key Finding

Serum Tryptase: 6.5 mcg/L
Reference Range: <11.0 mcg/L
Interpretation: Normal

Related Reports

August 31, 2021 – Initial Systemic Inflammatory Evaluation
October 13, 2021 – Peak Inflammatory Evaluation
December 15, 2021 – Rheumatology Recovery Evaluation
February 9, 2022 – Autoimmune Evaluation
March 7, 2022 – Sjögren’s Antibody Evaluation
July 11, 2022 – ESR/CRP Monitoring
Autoimmune Evaluation
Rheumatology Consultation Summary
Medical History Timeline

Navigation

Previous Report: July 11, 2022 – ESR and CRP Monitoring Evaluation
Next Report: Subsequent Laboratory Evaluation
Return to Laboratory Library
Return to Health Inventory

Observation

This report is another example of the value of preserving the complete diagnostic journey. Following the severe inflammatory episode of 2021, your physicians systematically evaluated multiple possible causes:

Rheumatoid arthritis markers — negative
Lupus-related markers — negative
Sjögren’s antibodies — negative
Infection studies — negative
Muscle injury markers — negative
Mast cell disorder evaluation — negative

The cumulative picture is important: the inflammatory illness was real and severe, but extensive testing did not identify a specific destructive autoimmune disease or infectious cause. This type of information will be especially valuable in the Section 3.7 – History of Systemic Inflammatory Illness portion of your Health Inventory.